Literature DB >> 16391184

18F-FDG PET/CT in the evaluation of adrenal masses.

Ur Metser1, Elka Miller, Hedva Lerman, Gennady Lievshitz, Shmuel Avital, Einat Even-Sapir.   

Abstract

UNLABELLED: Our purpose was to evaluate the performance of (18)F-FDG PET/CT, using data from both the PET and the unenhanced CT portions of the study, in characterizing adrenal masses in oncology patients.
METHODS: One hundred seventy-five adrenal masses in 150 patients referred for (18)F-FDG PET/CT were assessed. Final diagnosis was based on histology (n = 6), imaging follow-up (n = 118) of 6-29 mo (mean, 14 mo), or morphologic imaging criteria (n = 51). Each adrenal mass was characterized by its size; its attenuation on CT, expressed by Hounsfield units (HU); and the intensity of (18)F-FDG uptake, expressed as standardized uptake value (SUV). Receiver operating characteristic curves were drawn to determine the optimal cutoff values of HU and SUV that would best discriminate between benign and malignant masses.
RESULTS: When malignant lesions were compared with adenomas, PET data alone using an SUV cutoff of 3.1 yielded a sensitivity, specificity, positive predictive value, and negative predictive value of 98.5%, 92%, 89.3%, 98.9%, respectively. For combined PET/CT data, the sensitivity, specificity, positive predictive value, and negative predictive value were 100%, 98%, 97%, 100%, respectively. Specificity was significantly higher for PET/CT (P < 0.01). Fifty-one of the 175 masses were 1.5 cm or less in diameter. When a cutoff SUV of 3.1 was used for this group, (18)F-FDG PET/CT correctly classified all lesions.
CONCLUSION: (18)F-FDG PET/CT improves the performance of (18)F-FDG PET alone in discriminating benign from malignant adrenal lesions in oncology patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16391184

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  59 in total

Review 1.  FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma.

Authors:  Désirée Deandreis; Sophie Leboulleux; Caroline Caramella; Martin Schlumberger; Eric Baudin
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

Review 2.  Contemporary adrenal scintigraphy.

Authors:  Milton D Gross; Anca Avram; Lorraine M Fig; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-25       Impact factor: 9.236

3.  Something old, something new, PET in adrenal imaging.

Authors:  Milton D Gross; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07       Impact factor: 9.236

4.  PET-CT in the staging and treatment of non-small-cell lung cancer.

Authors:  Patricia Ibeas; Blanca Cantos; José Manuel Gasent; Begoña Rodríguez; Mariano Provencio
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

5.  [Adrenal tumors: principles of imaging and differential diagnostics].

Authors:  C Degenhart
Journal:  Radiologe       Date:  2014-10       Impact factor: 0.635

Review 6.  Management of Adrenal Masses.

Authors:  Hattangadi Sanjay Bhat; Balagopal Nair Tiyadath
Journal:  Indian J Surg Oncol       Date:  2016-12-17

7.  Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours?

Authors:  L Tessonnier; F Sebag; F F Palazzo; C Colavolpe; C De Micco; J Mancini; B Conte-Devolx; J F Henry; O Mundler; D Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

8.  Non-Linear Optical Imaging of Obesity-Related Health Risks: Review.

Authors:  Thuc T Le; Ji-Xin Cheng
Journal:  J Innov Opt Health Sci       Date:  2009-01-01

9.  Coherent anti-Stokes Raman scattering imaging of lipids in cancer metastasis.

Authors:  Thuc T Le; Terry B Huff; Ji-Xin Cheng
Journal:  BMC Cancer       Date:  2009-01-30       Impact factor: 4.430

Review 10.  The indeterminate adrenal mass in patients with cancer.

Authors:  A Sahdev; R H Reznek
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.